PhRMA
NOVEMBER 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times what they paid, on average, to acquire oncology medicines through 340B. These practices have implications for what patients pay out of pocket — and new research adds to the evidence.
Drug Topics
NOVEMBER 21, 2022
Israeli researchers find more than fivefold risk of developing systemic sclerosis among people with vitiligo.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
NOVEMBER 21, 2022
Research also focuses on connection between oral hygiene and other chronic diseases, neurological disorders, pulmonary infections.
European Pharmaceutical Review
NOVEMBER 21, 2022
The first-in-human gene therapy trial for heart failure patients with preserved ejection fraction (HFpEF) has been approved by the US Food & Drug Administration (FDA). SRD-001, the adenovirus associated virus (AAV)-based gene therapy is delivered to cardiac ventricular muscle cells via an intracoronary infusion system (produced by Sardocor, a clinical-stage gene therapy subsidiary of Medera), to increase the protein expression and functional activity of sarcoplasmic reticulum calcium ATPase
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
NOVEMBER 21, 2022
Individuals with COVID-19 reinfections were twice as likely to die and three times more likely to be hospitalized than those who did not have COVID-19 multiple times.
pharmaphorum
NOVEMBER 21, 2022
Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been predicted by industry observers. The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
NOVEMBER 21, 2022
The world is fast approaching the third anniversary of those days when we got our first inkling that a new disease was spreading in China. In the months that followed, normal life was suspended, then upended. At this point, everyone is well and truly sick of Covid-19 and the accommodations we have had to make to co-exist with it. So sick of it, in fact, that many people appear to have given up trying to avoid the SARS-CoV-2 virus.
Pharmacy Times
NOVEMBER 21, 2022
Although long-term health issues from COVID-19 are a major public health concern, evidence on post-acute COVID-19 syndrome, or post-COVID-19, is still limited, specifically among children and adolescents.
STAT
NOVEMBER 21, 2022
Northwest Biotherapeutics tried again, but its experimental treatment for brain cancer still falls short. Last Thursday in JAMA Oncology, Northwest Biotherapeutics and its scientific collaborators published the results of a large clinical trial showing its personalized cancer vaccine administered to patients with brain tumors reduced the risk of death by 20% compared to a group of patients taken from “external controls.
Pharmacy Times
NOVEMBER 21, 2022
The objective of the study was to estimate recent trends in cigarette use and health insurance coverage for US adults with and without mental health and SUD.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
NOVEMBER 21, 2022
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19 vaccines are just the beginning.” The unprecedented success of messenger RNA vaccines against the coronavirus is raising hopes that the technology could lead to new and better vaccines against a much older public health scourge: cancer.
Pharmacy Times
NOVEMBER 21, 2022
New system combines computational and experimental techniques to map evolutionary cancer lineages in their natural habitat of human tissue.
Drug Topics
NOVEMBER 21, 2022
New research indicates that glucose monitoring could lead to lifestyle changes during prediabetes.
Pharmacy Times
NOVEMBER 21, 2022
Approximately 2 years after patients were infected with COVID-19, non-hospitalized patients suffered from post-COVID-19 symptoms nearly 8% more than hospitalized patients.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Store News
NOVEMBER 21, 2022
The retailer opened its first small-format Rite Aid Pharmacy location, in Craigsville, Va., as part of a pilot program to improve access to pharmacy services.
The Checkup by Singlecare
NOVEMBER 21, 2022
What are Medicare Advantage Plans? | Enrollment Periods | Types of Medicare Advantage plans | How to compare plans | Best plans | Lowering costs. Medicare Advantage (Part C) plans continue to improve their coverage and become more popular. Medicare Part C plans may have certain advantages over Original Medicare, such as additional services and protections, but there may also be disadvantages.
ISPE
NOVEMBER 21, 2022
IT Infrastructure in the Current Life Science Company Environment. Trudy Patterson. Mon, 11/21/2022 - 10:06. iSpeak Blog. iSpeak. IT Infrastructure in the Current Life Science Company Environment. Christopher J. Reid. Arthur D. Perez, PhD. 21 November 2022. A look through the lens of GAMP 5® Second Edition. IT Infrastructure is a broad term that encompasses both the platforms upon which business applications run, as well as the services that keep these platforms and applications running.
STAT
NOVEMBER 21, 2022
STAUNTON, Va. — Honest Rx operates like any other pharmacy in the United States — with one big exception. It does not accept health insurance. Pharmacist and owner Matthew Garner opened his business in 2022, after over 20 years of working in and managing other pharmacies. In that time, companies like CVS have become behemoths by merging with pharmacy benefit managers and insurers.
The Checkup by Singlecare
NOVEMBER 21, 2022
What are Medigap plans? | Medigap vs. Medicare Advantage | Costs | How to enroll | FAQs . If you have recently enrolled in Medicare, you may have heard of Medigap plans and wondered how they work. Medigap policies , also known as Medicare Supplement policies, help cover some out-of- pocket costs associated with Original Medicare. There are multiple types of Medigap policies to choose from that fit your medical and financial needs.
Pharmaceutical Technology
NOVEMBER 21, 2022
Merck (MSD outside North America) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences, through a subsidiary, for $36.00 per each share in cash or for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
STAT
NOVEMBER 21, 2022
By 2050, drug-resistant infections caused by “superbugs” could kill 10 million people each year around the world. That’s more than the annual global death toll from cancer. In new research published this year in The Lancet, drug-resistant infections were found to be at least partly responsible for nearly 5 million deaths worldwide in 2019.
Fierce Healthcare
NOVEMBER 21, 2022
House lawmakers press Biden admin to change latest surprise billing rule. rking. Mon, 11/21/2022 - 17:18.
STAT
NOVEMBER 21, 2022
On Friday, oral health advocates across the globe got an early holiday gift from their longtime wish lists. They had been waiting their whole careers — for some STAT spoke with, up to nearly half a century — for oral health to be folded into conversations calling for health care access for all. The World Health Organization’s new Global Oral Health Status report took that first step.
The Luxe Pharmacist
NOVEMBER 21, 2022
Happy holidays love! My favorite time of the year is fast approaching and I couldn’t be more excited. Not only do the holidays bring me so much but Sagittarius season is also right around the corner So happy early birthday to all my fellow fiery archers out there! This year I turn 28 which I’m still trying to wrap my mind around, but at least I can age more gracefully with my favorite pharmaceutical toxins on the market and my holy grail skincare products, many of which are listed be
STAT
NOVEMBER 21, 2022
In the 1700s, French astronomer Jean-Jacques d’Ortous de Mairan noticed that the leaves of the mimosa plant opened towards the sun and closed at dusk. His discovery was in keeping with thousands of years of observations. But de Mairan also found that the plant followed the same rhythm even in the constant darkness of a cupboard, suggesting that some innate metronome kept the plant in sync with the rotation of the earth.
European Pharmaceutical Review
NOVEMBER 21, 2022
A study on the surge of new antimicrobial research has shown that despite almost a quarter of a million research papers (227,808) being published on the 12 bacterial families in the World Health Organization (WHO) global priority pathogen list of antibiotic-resistant bacteria from 2017, no new class of antibiotics has gone to market since 1987. Study data from Elsevier’s abstract and citation database Scopus, identified that 2,450 papers were published in 2021 on the pathogen WHO identified as m
STAT
NOVEMBER 21, 2022
A company being built from the ashes of IBM’s Watson Health division is launching new lines of business with a much different message: The real value is in the health data, not the fancy AI engine it might eventually power. The new venture, dubbed Merative, will focus on distributing data through channels designed to maximize its value for health plans, providers, pharmaceutical companies, employers and other businesses.
PharmaVoice
NOVEMBER 21, 2022
Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.
Fierce Pharma
NOVEMBER 21, 2022
ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win. aliu. Mon, 11/21/2022 - 16:29.
Drug Store News
NOVEMBER 21, 2022
Designed to keep its key visual elements, the new product layout includes enhanced readability of product names and varieties.
Drug Topics
NOVEMBER 21, 2022
This is the first FDA-approved ADC for platinum-resistant disease, according to ImmunoGen.
PharmaVoice
NOVEMBER 21, 2022
The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.
STAT
NOVEMBER 21, 2022
Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs that target bone marrow diseases to its research pipeline. The all-cash deal values Imago at $36 per share, or a 107% premium from its closing price on Friday.
Fierce Pharma
NOVEMBER 21, 2022
Pfizer's Paxlovid access brought into question as WTO set to discuss patent waiver—again. aliu. Mon, 11/21/2022 - 11:21.
Expert insights. Personalized for you.
262 
Let's personalize your content